Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Fusen Pharmaceutical Company Limited
福森藥業有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1652)

VOLUNTARY ANNOUNCEMENT
"MEASARTAN POTASSIUM TABLETS" APPROVED FOR MARKETING

The board of directors (the "**Board**") of Fusen Pharmaceutical Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that "Measartan Potassium Tablets* (美阿沙坦鉀片)" (trademark: Kuaonuoping* 快諾平) developed by Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited* (嘉亨(珠海橫琴)醫藥科技有限公司), a wholly-owned subsidiary of the Group, has obtained the approval for marketing from the National Medical Products Administration of the PRC for the treatment of primary hypertension.

Azilsartan medoxomil potassium, the main ingredient of "Measartan Potassium Tablets* (美阿沙坦鉀片)", is an angiotensin II receptor antagonist. After oral ingestion, it is rapidly converted into the active ingredient azilsartan, which can lower blood pressure by blocking the angiotensin II hormone.

In the overall renin-angiotensin system (RAS) market, more than 80% of the market share is occupied by "Sartan" monotherapy and various combination therapy drugs. As their sales in 2022 exceeded RMB10 billion, "Sartan" antihypertensive drugs hold an important position in the entire hypertension medication family.

"Measartan Potassium Tablets* (美阿沙坦鉀片)" are Category B medicines under the National Healthcare Security Administration* (國家醫療保障局), with no restrictions on indications and disease types as to insurance. They have now become a first-line antihypertensive agent for treating primary hypertension on adults both domestically and internationally with significant, long-lasting and stable antihypertensive effects, stronger organ-protective effects and other advantages. The "Measartan Potassium Tablets* (美阿沙坦鉀片)" developed by the Company are consistent with the original formulation. Through pharmaceutical and clinical (BE) studies, their quality and efficacy have reached the same level as those of reference-listed drugs, ensuring that the medication is safe and effective for patients, with a risk-benefit ratio comparable to those of reference-listed drugs.

"Measartan Potassium Tablets* (美阿沙坦鉀片)" is another important product of the Group, further enriching the Group's medical product pipeline in the field of the blood circulatory system. The two specifications of 40mg and 80mg are suitable for patients with mild-to-moderate hypertension and severe hypertension respectively. The product will provide additional treatment options for adult patients of primary hypertension after launch.

By order of the Board
Fusen Pharmaceutical Company Limited
Mr. Cao Zhiming
Chairman and Executive Director

Hong Kong, 14 November 2025

As at the date of this announcement, the Board of the Company comprises Mr. Cao Zhiming (Chairman), Mr. Hou Taisheng, Mr. Chi Yongsheng and Ms. Meng Qingfen as executive Directors and Mr. Lee Kwok Tung Louis, Dr. To Kit Wa and Mr. Yu Ho Ming as independent non-executive Directors.

* *For identification purposes only*